Comprehensive services

• Full dossiers for health technology assessments in Europe• European core values dossiers• Market analysis• Real-world analysis and analysis of care provision• Market access and pricing strategies• Clinical trials

Exhibitor: IGES Institut GmbH

Genekam is working on potential therapeutic molecules and antibodies against pandemic influenza viruses

Genekam is working on potential therapeutic molecules and antibodies against pandemic influenza viruses

Exhibitor: Genekam Biotechnology AG

Gentle treatment for premature babies with lung diseases

Premature babies who are born before their lungs have finished maturing often suffer from a lack of surfactant – a substance necessary for lung development. They are also particularly susceptible to illnesses of the respiratory organ, which have to be…

Exhibitor: Fraunhofer Institute for Toxicology and Experimental Medicine ITEM

Fraunhofer launches German-Australian iCAIR project

Researchers from the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM have teamed up with colleagues from the Hannover Medical School (MHH) and Griffith University’s Institute for Glycomics (IfG) in Gold Coast, Australia, in the Fraunhofer International Consortium for Anti-Infective…

Exhibitor: Fraunhofer Institute for Toxicology and Experimental Medicine ITEM

Dortmund Alliance Receives 11 Million Euros for the Development of New Lead Compounds

Dortmund, 01.05.2018 ++++Drug Discovery Hub Dortmund (DDHD) is the name of the new initiative at the Zentrum für integrierte Wirkstoffforschung (ZIW) of the TU Dortmund University (TU), which got started on 1 April 2018. Scientists from eight institutions combine their…

Exhibitor: Taros Chemicals

Taros Appoints Torsten Hoffmann as Senior Vice President Drug Discovery

Dortmund, October 1, 2018 ++++Taros Chemicals GmbH & Co. KG today announced the appointment of Dr Torsten Hoffmann as Senior Vice President Drug Discovery, effective October 1st, 2018. In his role, Torsten will further strengthen and accelerate Taros’ continued growth…

Exhibitor: Taros Chemicals

CARDIOREG alliance: ZeClinics and Taros to develop new heart regeneration therapies

Barcelona, Spain & Dortmund, Germany, 30. January 2019 ++++ ZeClinics SL, a biotech firm focused on preclinical services with zebrafish, announced today that they have entered into a joint research agreement with Taros Chemicals GmbH, a company specializing in drug…

Exhibitor: Taros Chemicals

ERICA GCP-compliant medical image management platform for clinical trials.

In 2017 pharmtrace launched its tried and tested GCP-compliant image management platform (ERICA) as a “cloud enabled” SaaS ("Software as a Service") platform to enable customers to directly manage their clinical trial images and to take full control of all…

Exhibitor: pharmtrace klinische Entwicklung GmbH

Medigene publishes topline interim data from ongoing Phase I/II clinical trial with DC vaccines in AML patients

Topline-data from first half of treatment period (one year) Very good feasibility of the manufacture of the vaccine from patient-derived cells Excellent safety and tolerability profile Preliminary data on overall survival and progression-free survival Presentation of further details planned at…

Exhibitor: Medigene AG

RCI Regensburg – Top-notch research from East Bavaria

The Regensburg Center for Interventional Immunology (RCI) is being accommodated at the BioPark until the completion of the new research building. Here the foundations for the development of new immunotherapies will be researched, to make therapeutic interventions for cancer, infectious…

Exhibitor: BioPark Regensburg

RCHST follows RCBE to the BioPark Regensburg

After the Regensburg Center of Biomedical Engineering (abb. RCBE) was able to move into its own rooms in the new building on the campus at OTH Regensburg, the premises at the BioPark will now be used by the Regensburg Center…

Exhibitor: BioPark Regensburg

Winner 2018 CRO Leadership Award

“The whole bioskin team is honored and grateful that we received the CRO Leadership Award in the categories Capability, Expertise, Quality and Reliability. With over 25 years of experience dedicated to clinical research in dermatology, bioskin offers full service across…

Exhibitor: bioskin GmbH

New HTS Platform for Personalized Tumor Therapy

The Division of Personalized Tumor Therapy of the Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, based at the BioPark Regensburg, has founded a new working group “High-Throughput Drug and Target Discovery”. Its goal is to generate patient-derived preclinical in-vitro…

Exhibitor: BioPark Regensburg

Corporate company film

Exhibitor: bioskin GmbH